Charles Schwab Investment Management Inc. Trims Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Charles Schwab Investment Management Inc. reduced its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 5.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 236,157 shares of the specialty pharmaceutical company’s stock after selling 14,189 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.12% of ANI Pharmaceuticals worth $13,055,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. US Bancorp DE lifted its position in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after acquiring an additional 531 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of ANI Pharmaceuticals by 3.7% during the 4th quarter. Bank of New York Mellon Corp now owns 123,832 shares of the specialty pharmaceutical company’s stock worth $6,845,000 after purchasing an additional 4,404 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $1,741,000. Principal Financial Group Inc. lifted its holdings in ANI Pharmaceuticals by 4.2% in the fourth quarter. Principal Financial Group Inc. now owns 93,777 shares of the specialty pharmaceutical company’s stock valued at $5,184,000 after acquiring an additional 3,816 shares during the last quarter. Finally, Legato Capital Management LLC acquired a new position in ANI Pharmaceuticals during the fourth quarter worth $334,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price on the stock. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Finally, Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $79.75.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock worth $191,776 in the last quarter. 12.70% of the stock is owned by company insiders.

ANI Pharmaceuticals Trading Down 0.1 %

Shares of ANIP stock opened at $64.26 on Friday. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81. The company has a market capitalization of $1.40 billion, a P/E ratio of -116.84 and a beta of 0.63. The firm has a 50-day moving average price of $59.39 and a 200 day moving average price of $58.17. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.